An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B
Latest Information Update: 15 Jun 2025
At a glance
- Drugs ANB 002 (Primary)
- Indications Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms MAGNOLIA
- Sponsors Biocad
Most Recent Events
- 20 Feb 2025 Status changed from not yet recruiting to recruiting.
- 27 Nov 2024 New trial record